Previous 10 | Next 10 |
SHANGHAI and SAN FRANCISCO , May 19, 2020 /PRNewswire/ -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrat...
Zai Lab (NASDAQ: ZLAB ) announces dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrational trial evaluating the combination of sulbactam and durlobactam (SUL-DUR) for the treatment of carbapenem-resistant Acinetobacter...
SHANGHAI and SAN FRANCISCO, May 18, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese patient in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrati...
COVID-19 Pandemic Sorrento Therapeutics (SRNE), a San Diego-China biotech, reported that its anti-SARS-CoV-2 antibody, STI-1499, completely inhibited SARS-CoV-2 virus infection from interacting with the ACE2 receptor after four days of incubation (see story ). In preclinical studies, the mo...
Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rat e 1 Optune is Za...
Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...
Coronavirus Pandemic Junshi Biosciences [HK:1877] out-licensed ex-China rights for a therapeutic antibody aimed at preventing and treating COVID-19 to Eli Lilly (LLY) (see story ). JS016 is a recombinant fully human monoclonal neutralizing antibody that is specific to the SARS-CoV-2 surface...
SHANGHAI, China, and SAN FRANCISCO, May 06, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted pr...
SHANGHAI, China and SAN FRANCISCO, April 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today announced that members of management will be presenting at the upcoming BofA Se...
Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs. More news on: Adverum Biotechnologies, Inc., Alector, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...